CSF1R and neoplasm: In mouse models of cancer, CSF1R blockades synergize with the agonistic CD40 antibodies to remove inhibitory immune populations and to drive endogenous antitumor immune responses, resulting in improved tumor clearance and significantly lengthened overall survival [102].